I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Avacta Group PLC (AVCT)

Avacta Group PLC

Director/PDMR Shareholding
RNS Number : 0325P
Avacta Group PLC
04 June 2020
 

 


04 June 2020

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

Director/PDMR Shareholdings

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces it has granted a total of 6,321,880 options over ordinary shares of 10p each ("Ordinary Shares") to certain directors the Company (the "Options").

 

These Options were granted under the Company's Long Term Incentive Plan*, Avacta Group plc Executive Share Option Scheme as set out below:  

 

 

Director

Position

Number of Options granted

Exercise Price

Alastair Smith

CEO

868,260*

17.25p

Alastair Smith

CEO

4,000,000**

10p

Tony Gardiner

CFO

453,620*

17.25p

Tony Gardiner

CFO

1,000,000**

10p

 

 

* The vesting conditions are split 50% based on share price performance and 50% based on the achievement of significant commercial and technical milestones over a period up to 31 December 2021, which represents the second tranche of the 2019 LTIP award, with the exercise price based on the closing mid-market price on 31 December 2019.

 

** The vesting conditions are based on the share price performance over the three year period up to 31 December 2022, which represents the 2020 LTIP award, with the exercise price based on the ordinary share nominal value of 10p.

 

Following these awards and the lapsing of some historic share awards which had not met a share price condition in January 2020, the total number of options held by the directors were as set out below:

 

 

Director

Position

Number of Options held

Alastair Smith

CEO

5,908,525

Tony Gardiner

CFO

2,057,521

 

 

Eliot Forster, Non-executive Chairman, said:

 

"Following the significant developments within the Group during the course of 2020, I am pleased to confirm that the Remuneration Committee has been able to conclude the changes to the equity arrangements of Alastair and Tony.  These arrangements continue to align the interests of the Executive Directors with the longer-term interests of our shareholders through stretching targets on commercial and operational delivery combined with share price performance."

 

 

 

- Ends -

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel: +44 (0) 844 414 0452

www.avacta.com

 

 

finnCap Ltd (Nomad and Joint Broker)

Geoff Nash / Giles Rolls / Teddy Whiley - Corporate Finance

Tim Redfern - ECM

 

 

Tel: +44 (0) 207 220 0500

www.finncap.com

 

 

Zeus Capital Limited (Joint Broker)

John Goold / Rupert Woolfenden - Corporate Broking

Tel: +44 (0)203 829 5000

www.zeuscapital.co.uk

Yellow Jersey  (Financial Media and IR)

Sarah Hollins

Henry Wilkinson

 

Zyme Communications  (Trade and Regional Media)

Katie Odgaard

 

 

Tel: +44 (0)203 004 9512

avacta@yellowjerseypr.com

 

 

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com  

 

 

 

About Avacta Group plc (www.avacta.com)

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

 

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost. 

 

 

Avacta's pre|CISION platform, activates chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thus improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

 

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic later in 2020 or early 2021.

 

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a collaboration with LG Chem to develop treatments for autoimmune and inflammatory diseases worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and a joint venture in South Korea with Daewoong Pharmaceuticals to develop the next generation of stem cell therapies that incorporate Affimer immuno-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

 

The Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alastair Smith

2. 

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

LTIP

Exercise Price(s)

Volume(s)

17.25 pence

868,260

 

LTIP

Exercise Price(s)

Volume(s)

10.00 pence

4,000,000

d)

Aggregated information:

· Aggregated volume

· Price

Grant of 868,260 options over Ordinary Shares at an exercise price of 17.25p

Grant of 4,000,000 options over Ordinary Shares at an exercise price of 10p

e)

Date of the transaction

04 June 2020

f)

Place of the transaction

Outside a trading venue

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tony Gardiner

2. 

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

LTIP

Exercise Price(s)

Volume(s)

17.25 pence

453,620

 

LTIP

Exercise Price(s)

Volume(s)

10.0 pence

1,000,000

d)

Aggregated information:

· Aggregated volume

· Price

Grant of 453,620 options over Ordinary Shares at an exercise price of 17.25p

Grant of 1,000,000 options over Ordinary Shares at an exercise price of 10p

e)

Date of the transaction

04 June 2020

f)

Place of the transaction

Outside a trading venue

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKKQBKABKDPAK
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close